TREMELIMUMAB for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 21 adverse event reports in the FDA FAERS database where TREMELIMUMAB was used for Transitional cell carcinoma.
Most Reported Side Effects for TREMELIMUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pyrexia | 178 | 7.5% | 21 | 143 |
| Diarrhoea | 136 | 5.7% | 31 | 95 |
| Death | 116 | 4.9% | 116 | 17 |
| Colitis | 115 | 4.8% | 26 | 76 |
| Pneumonitis | 87 | 3.6% | 44 | 59 |
| Pneumonia | 85 | 3.6% | 36 | 76 |
| Sepsis | 82 | 3.4% | 35 | 71 |
| Vomiting | 78 | 3.3% | 11 | 70 |
| Febrile neutropenia | 72 | 3.0% | 30 | 60 |
| Malignant neoplasm progression | 68 | 2.9% | 22 | 9 |
| Abdominal pain | 64 | 2.7% | 22 | 60 |
| Dehydration | 61 | 2.6% | 21 | 58 |
| Biliary tract infection | 58 | 2.4% | 0 | 58 |
| Drug-induced liver injury | 57 | 2.4% | 11 | 36 |
| Dyspnoea | 57 | 2.4% | 23 | 32 |
Other Indications for TREMELIMUMAB
Pancreatic carcinoma (530)
Hepatocellular carcinoma (487)
Non-small cell lung cancer (448)
Pancreatic carcinoma metastatic (142)
Small cell lung cancer (80)
Squamous cell carcinoma of head and neck (68)
Bladder transitional cell carcinoma (51)
Bladder cancer (44)
Non-small cell lung cancer metastatic (44)
Neoplasm malignant (42)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)